Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | 24 healthy age and sex-matched controls |
| |
| Patients with acute Ischemic stroke | 24 patients between 50-70 years having neurological symptoms of acute ischemic stroke will be included. Patients with acute hemorrhagic stroke, Parkinson's disease, dementia, Alzheimer's disease, malignancy, and central nervous system infection will be excluded. |
| |
| Control rats | 8 rats will be subjected to a Sham operation and will be injected intramuscularly immediately after the operation with an equivalent 0.9% saline solution. After 24 hours they will be sacrificed. |
| |
| Rats with ischemic stroke | 8 rats will be subjected to bilateral common carotid artery occlusion (CCAO) for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with an equivalent 0.9% saline solution. They will be sacrificed after 24 hours of reperfusion. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Serum Iron | Diagnostic Test | Serum iron levels in study groups |
|
| Measure | Description | Time Frame |
|---|---|---|
| Iron levels | Serum iron levels in ischemic patients and control | 6 months |
| Alpha-synuclein levels | Alpha-synuclein levels in RBCs in ischemic patients and control | 6 months |
| Levels of Soluble lymphocyte activation gene-3 | Serum soluble lymphocyte activation gene-3 in ischemic patients and control | 6 months |
| levels of iron, alpha-synuclein, and soluble lymphocyte activation in relation to stroke severity and infarction size | stroke severity will be evaluated by the National Institutes of Health Stroke Scale (NIHSS) and size of infarction will be detected by brain CT | 6 months |
| Iron levels in brain of rats | Iron levels in brain homogenate of rats in the three rat groups | 2 months |
| Levels of Alpha-synuclein expression in brain of rats | Alpha-synuclein expression in brain of rats in different groups | 2 months |
| Levels of Lymphocyte activation gene-3 expression in brain of rats | lymphocyte activation gene-3 expression in brain of rats in different groups | 2 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with neurological symptoms of acute ischemic stroke
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Asmaa Abdelmageed Muhammed | Aswan University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aswan University Hospital | Aswān | 81528 | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34675870 | Background | Malfertheiner K, Stefanova N, Heras-Garvin A. The Concept of alpha-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders. Front Neurol. 2021 Oct 5;12:737195. doi: 10.3389/fneur.2021.737195. eCollection 2021. | |
| 35847179 | Background | Wu Q, Wei C, Guo S, Liu J, Xiao H, Wu S, Wu B, Liu M. Acute iron overload aggravates blood-brain barrier disruption and hemorrhagic transformation after transient focal ischemia in rats with hyperglycemia. IBRO Neurosci Rep. 2022 Jul 3;13:87-95. doi: 10.1016/j.ibneur.2022.06.006. eCollection 2022 Dec. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Rats with ischemic stroke + deferoxamine | 8 rats will be subjected to bilateral CCAO for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with deferoxamine (200 mg/kg), They will be sacrificed after 24 hours of reperfusion. |
|
| RBCs Alpha-synuclein | Diagnostic Test | α-syn levels in RBCs |
|
|
| Serum Soluble lymphocyte activation gene | Diagnostic Test | sLAG-3 in the serum of study groups |
|
|
| Brain computed tomography | Radiation | Brain CT of patients after admission |
|
|
| Brain Iron | Diagnostic Test | Iron in brain homogenate of rats |
|
| Brain Alpha-synuclein | Diagnostic Test | α-syn expression in rat's brain |
|
|
| Brain lymphocyte activation gene | Diagnostic Test | LAG-3 expression in rat's brain |
|
|
| Deferoxamine | Drug | intramuscular deferoxamine (200 mg/kg) injection to rats |
|
| 31767524 | Background | Yoon CW, Park HK, Bae EK, Rha JH. Sleep Apnea and Early Neurological Deterioration in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2020 Feb;29(2):104510. doi: 10.1016/j.jstrokecerebrovasdis.2019.104510. Epub 2019 Nov 22. |
| 35170503 | Background | Zhao L, Wang H, Xu K, Liu X, He Y. Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications. Chin Med J (Engl). 2022 May 20;135(10):1203-1212. doi: 10.1097/CM9.0000000000001981. |
| ID | Term |
|---|---|
| D002545 | Brain Ischemia |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003676 | Deferoxamine |
| ID | Term |
|---|---|
| D006877 | Hydroxamic Acids |
| D006898 | Hydroxylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D006880 | Hydroxy Acids |
| D002264 | Carboxylic Acids |
Not provided
Not provided